 LEXINGTON, Mass., Jan. 21, 2022 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that the topline data obtained with KB295, a novel Microbiome Metabolic Therapy MMTTM, in mild-to-moderate ulcerative colitis UC, will be presented virtually at the 2022 Crohns and Colitis Congress. 